Companies
Biossance
launched by biotech firm Amyris in 2016, commercialized lab-made bio-identical squalane fermented from sugarcane-derived sucrose using engineered Saccharomyces cerevisiae, positioning "clean beauty" as scientifically rigorous rather than purely natural-marketing-driven.
- Country
- United States
bio-squalane
us
Coverage
| CN | EU | US | |
|---|---|---|---|
| specialty-fine-chem | ✓ | ✓ | ✓ |
Regulatorsfdanmpareach
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | Invested $300M-$400M by Amyris, Inc. during its ownership | beautyindependent.com · thegrocer.co.uk |
| Capacity | Can produce the world's yearly supply of squalane using 1 sq km of land | amyris.com · marketscreener.com |
| Certification | Roundtable on Sustainable Biomaterials (RSB) certified fermentation plant; My Green Lab Platinum Certified facility | bbbprograms.org · biossance.com |
| Production site | Brazil (sugarcane mill and fermentation plant); also manufactured at sites in the United States and Europe | amyris.com · marketscreener.com |
| Revenue | Approximately $100 million in 2022; $300 million total since 2015 launch | thg.ir-data.com · beautyindependent.com |
Independent sources: amyris.com · bbbprograms.org · beautyindependent.com · marketscreener.com · thegrocer.co.uk · thg.ir-data.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Cosmetics, nutricosmetics & wellness | specialty-fine-chem | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.